Newly approved oral medication slows rheumatoid arthritis joint damage

Newly approved oral medication slows rheumatoid arthritis joint damage

A Phase 3 clinical trial demonstrates that tofacitinib improves disease activity and inhibits progression of joint damage in rheumatoid arthritis (RA) patients who did not respond to methotrexate (MTX). Results of the 12-month interim analysis of the efficacy of tofacitinib appear in Arthritis & Rheumatism, a journal published by Wiley on behalf of the American College of Rheumatology (ACR).

RA is a chronic, autoimmune disease that causes inflammation, pain and swelling of the joints. Over time, RA may destroy joints, impair daily function, and lead to significant disability. The World Health Organization (WHO) estimates that RA affects up to one percent of individuals worldwide and 1.3 million of those are Americans according to the ACR.

Read more

Read more

  • American Society for Surgery of the Hand
  • American Academy of Orthopaedic Surgeons
  • Health Influencer
  • American Board of Orthopaedic Surgery-Orthopaedic Surgery
  • American Board of Orthopaedic Surgery-Orthopaedic Surgery of the Hand
  • American Board of Orthopaedic Surgery-Orthopaedic Sports Medicine